Table 2 Serum advanced protein oxidation products (AOPPs), ferric reducing antioxidant power (FRAP), pro-oxidant-antioxidant balance (PAB) and ischemia modified albumin (IMA) levels of the patients with pulmonary embolism (PE) and the controls
From: Importance of oxidative stress in the evaluation of acute pulmonary embolism severity
Controls (n:21) | Low-risk (n:14) | Intermediate-risk (n:16) | High-risk (n:17) | p | |
|---|---|---|---|---|---|
IMA (U/mL) | 10.43 ± 1.96 | 10.12 ± 2.23 | 10.87 ± 2.67 | 14.66 ± 5.54 | < 0.01 |
AOPPs (µM chloramine T) | 39.6 ± 6.8 | 50.7 ± 13.4 | 57.7 ± 18.8 | 81.4 ± 22.9 | < 0.001 |
FRAP (M uric acids) | 0.20 ± 0.03 | 0.10 ± 0.03 | 0.10 ± 0.03 | 0.11 ± 0.05 | > 0.05 |
PAB (% H2O2) | 40.2 ± 3.9 | 89.1 ± 26.7 | 96.2 ± 19.9 | 105.3 ± 21.8 | < 0.01 |